. 2018 Jul 30;18(9):259–264. doi: 10.1016/j.bjae.2018.05.007

Table 4.

Advised time between last dose of a DOAC and surgery

Renal function and related half-life	DOAC and current dose	Time of last dose before surgery (h)
Renal function and related half-life	DOAC and current dose	Low-bleeding-risk surgery (two to three half-lives between last dose and surgery)	High-bleeding-risk surgery (four to five half-lives between last dose and surgery)
CrCl ≥50 ml min⁻¹ (half-life: 7–8 h)	Apixaban 5 mg twice daily	24	48–72
CrCl 30–49 ml min⁻¹ (half-life: 17–18 h)	Apixaban 5 mg twice daily	48	72
CrCl ≥50 ml min⁻¹ (half-life: 5–9 h)	Rivaroxaban 20 mg once daily	24	48–72
CrCl 30–49 ml min⁻¹ (half-life: 9–13 h)	Rivaroxaban 20 mg once daily	48	72
CrCl ≥50 ml min⁻¹ (half-life: 12–17 h)	Dabigatran 150 mg twice daily	24	48–72
CrCl 30–49 ml min⁻¹ (half-life: 13–23 h)	Dabigatran 150 mg twice daily	48–72	96